Cancer Therapeutic and Diagnostic Products Discovered from the Protective Immune Responses of Patients

MabVax is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer.

About MabVax Therapeutics

Home

MabVax Discovery Platform

MabVax Discovery Platform

We have developed a proprietary approach to the discovery and development of novel fully human antibody therapies and diagnostic agents.

View Platform
Clinical Development

Clinical Development

Our portfolio includes fully human antibodies that are being developed to address unmet medical needs in several difficult to treat cancers such as pancreatic, lung, sarcoma, ovarian, and breast cancer.

View Product Pipeline

Investor Relations

MabVax Therapeutics Holdings, Inc. NASDAQ: MBVX
Price
Change
Volume
Day Range
52 Week Range

Sign Up for Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign Up Now